FIELD: medicine.
SUBSTANCE: invention relates to onco-hematology. Prediction method is proposed for lymphoma clinical course severity and treatment efficiency: prior to treatment, proinflammatory cytokines interleukins IL-1β and IL-6 levels in blood serum are determined, and relative part of lymphoid tumour cells, bearing surface receptors to cytokines IL-1β and IL-6, are determined in marrow smears. Subject to IL-1β level and relative part of lymphoid tumour cells, bearing receptors to cytokines IL-1β and IL-6, conclusion of favourable or unfavourable prognosis is made. The method has high sensitivity, specificity, and prognostic value.
EFFECT: increase in prediction accuracy of lymphoma clinical course severity and treatment efficiency.
4 ex, 12 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREDICTING EFFICIENCY OF TREATMENT OF PATIENTS WITH HIGH GRADE NON-HODGKIN LYMPHOMA | 2013 |
|
RU2533816C2 |
| METHOD OF LYMPH THERAPY EFFICIENCY FORECAST | 2007 |
|
RU2349263C2 |
| METHOD FOR PREDICTING THE COURSE OF PRIMARY MEDIASTINAL B-LARGE CELL LYMPHOMA | 2021 |
|
RU2772187C1 |
| LABORATORY METHOD FOR DETECTING EXTENSIVE STAGES OF LYMPHOPROLIFERATIVE DISORDER | 2017 |
|
RU2657804C2 |
| METHOD OF DIFFERENTIATED TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOSARCOMAS OF LYMPHOID ORGANS IN ADULTS | 2009 |
|
RU2421217C2 |
| METHOD FOR PREDICTING THE COURSE OF CHRONIC LYMPHOCYTIC LEUKEMIA | 2022 |
|
RU2788816C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF RECURRENCE OF DIFFUSE LARGE B-CELL LYMPHOMA | 2021 |
|
RU2758126C1 |
| COMBINED CELL TRANSPLANT BASED ON LYMPHOKINE-ACTIVATED KILLERS AND DENDRITE CELLS, METHOD FOR PRODUCTION THEREOF AND METHOD FOR TREATMENT AND PROPHYLAXIS OF MALIGNANT, INFECTIVE DISEASES AND IMMUNODEFICIENT CONDITIONS | 2006 |
|
RU2309753C1 |
| METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
| METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS | 2023 |
|
RU2821659C1 |
